nach oben

European Radiology

Erschienen in:

01.08.2007 | Oncology

Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging

verfasst von: Fabian Kiessling, Manfred Jugold, Eva C. Woenne, Gunnar Brix

Erschienen in: European Radiology | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

The switch to an angiogenic phenotype is an important precondition for tumor growth, invasion and spread. Since newly formed vessels are characterized by structural, functional and molecular abnormalities, they offer promising targets for tumor diagnosis and therapy. Previous studies indicate that MRI is valuable to assess vessel morphology and function. It can be used to distinguish between benign and malignant lesions and to improve delineation of proliferating areas within heterogeneous tumors. In addition, tracer kinetic analysis of contrast-enhanced image series allows the estimation of well-defined physiological parameters such as blood volume, blood flow and vessel permeability. Frequently, changes of these parameters during cytostatic, anti-angiogenic and radiation therapy precede tumor volume reduction. Moreover, target-specific MRI techniques can be used to elucidate the expression of angiogenic markers at the molecular level. This review summarizes strategies for non-invasive characterization of tumor vascularization by functional and molecular MRI, hereby introducing representative preclinical and clinical applications.

Folkman J (1970) Tumor angiogenesis therapeutic implication. N Engl J Med 285:1182–1186

Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumor. Ann Surg 175:409–416PubMedCrossRef

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257PubMedCrossRef

Folkman J (1995) Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757–1763PubMedCrossRef

Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. The Oncologist 9:10–17PubMedCrossRef

Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nature Rev Cancer 3:401–410CrossRef

Vaupel P, Harrison L (2004) Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9:4–9PubMedCrossRef

Garcea G, Lloyd TD, Gescher A, Dennison AR, Steward WP, Berry DP (2004) Angiogenesis of gastrointestinal tumours and their metastases-a target for intervention? Eur J Cancer 40:1302–1313PubMedCrossRef

Folkman J (2003) Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2:127–133

10.

Gilad AA, Israely T, Dafni H, Meir G, Cohen B, Neeman M (2005) Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: the role of stroma cells in tumor angiogenesis. Int J Cancer 117:202–211PubMedCrossRef

11.

Overall CM, Kleifeld O (2006) Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–239PubMedCrossRef

12.

Folkman J (2004) Endogenous angiogenesis inhibitors. APMIS 112:496–507PubMedCrossRef

13.

Jain RK (2003) Molecular regulation of vessel maturation. Nature Med 9:685–693PubMedCrossRef

14.

Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev 4:423–426

15.

Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 15:967–974CrossRef

16.

Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMed

17.

Huston J, Rufenacht DA, Ehman, RL, Wiebers DO (1991) Intracranial aneurysms and vascular malformations: Comparison of time-of-flight and phase-contrast MR angiography. Radiology 16:531–538

18.

Kesava P, Baker E, Mehta M, Turski P (1996) Staging of arteriovenous malformations using three-dimensional time-of-flight MR angiography and volume-rendered displays of surface anatomy. Am J Roentgenol 167:605–609

19.

Essig M, Reichenbach JR, Schad LR, Schoenberg SO, Debus J, Kaiser WA (1999) High-resolution MR venography of cerebral arteriovenous malformations. Magn Reson Imaging 17:1417–1425PubMedCrossRef

20.

Kobayashi H, Sato N, Kawamoto S, Saga T, Hiraga A, Ishimori T, Konishi J, Togashi K, Brechbiel MW (2001) 3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent. Magn Reson Med 46:579–585PubMedCrossRef

21.

Kobayashi H, Brechbiel MW (2003) Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging 2:1–10PubMedCrossRef

22.

Kiessling F, Heilmann M, Lammers T, Ulbrich K, Subr V, Peschke P, Waengler B, Mier W, Schrenk HH, Bock M, Schad L, Semmler W (2006) Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. Bioconjug Chem 17:42–51PubMedCrossRef

23.

Fink C, Kiessling F, Bock M, Lichy M, Misselwitz B, Peschke P, Fusenig NE, Grobholz R, Delorme S (2003) High-resolution 3D MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature. J Magn Reson Imag 18:59–65CrossRef

24.

Kiessling F, Greschus S, Lichy MP, Bock M, Fink C, Vosseler S, Moll J, Mueller MM, Fusenig NE, Traupe H, Semmler W (2004) Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis. Nat Med 10:1133–1138PubMedCrossRef

25.

Tropres I, Lamalle L, Peoc’h M, Farion R, Usson Y, Decorps M, Remy C (2004) In vivo assessment of tumoral angiogenesis. Magn Reson Med 51:533–541PubMedCrossRef

26.

Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, Decorps M (2001) Vessel size imaging. Magn Reson Med 45:397–408PubMedCrossRef

27.

Kiselev VG, Strecker R, Ziyeh S, Speck O, Hennig J (2005) Vessel size imaging in humans. Magn Reson Med 53:553–563PubMedCrossRef

28.

Weber MA, Risse F, Giesel FL, Schad LR, Kauczor HU, Essig M (2005) Perfusion measurement using the T2* contrast media dynamics in neuro-oncology. Physical basics and clinical applications. Radiologe 5:618–632CrossRef

29.

Cha S (2004) Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 15:279–289PubMedCrossRef

30.

Steward GN (1894) Researches on the circulation time in organs and on the influence which affect it, parts I-III. J Physiol 15:1

31.

Meier P, Zierler KL (1954) On the theory of the indicator-dilution method for measurement of blood flow and volume. Appl Physiol 6:731–744

32.

Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 36:715–725PubMedCrossRef

33.

Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results. Magn Reson Med 36:726–736PubMedCrossRef

34.

Daldrup HE, Shames DM, Husseini W, Wendland MF, Okuhata Y, Brasch RC (1998) Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 40:537–543PubMedCrossRef

35.

Ichikawa T, Arbab AS, Araki T, Touyama K, Haradome H, Hachiya J, Yamaguchi M, Kumagai H, Aoki S (1999) Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinoma. AJR 173:207–213PubMed

36.

Kuhl CK, Bieling H, Gieseke J, Ebel T, Mielcarek P, Far F, Folkers P, Elevelt A, Schild HH (1997) Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. Radiology 202:87–95PubMed

37.

Kvistad KA, Lundgren S, Fjosne HE, Smenes E, Smethurst HB, Haraldseth O (1999) Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imaging. Acta Radiol 40:45–51PubMedCrossRef

38.

Fuss M, Wenz F, Essig M, Muenter M, Debus J, Herman TS, Wannenmacher M (2001) Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys 51:478–482PubMedCrossRef

39.

Padhani AR, Leach MO (2005) Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 30:324–341PubMedCrossRef

40.

Akella SN, Twieg DB, Mikkelsen T, Hochberg FH, Grossman S, Cloud GA, Nabors LB (2004) Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging 20:913–922PubMedCrossRef

41.

Kaiser WA, Zeitler E (1989) MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 170:681–686PubMed

42.

Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101–110PubMed

43.

Kuhl CK, Schild HH (2000) Dynamic image interpretation of MRI of the breast. J Magn Reson Imaging 12:965–974PubMedCrossRef

44.

Kiessling F, Lichy M, Grobholz R, Heilmann M, Farhan N, Michel MS, Trojan L, Ederle J, Abel U, Kauczor HU, Semmler W, Delorme S (2004) Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. Eur Radiol 14:1793–1801PubMed

45.

Barentsz JO, Engelbrecht M, Jager GJ, Witjes JA, de LaRosette J, van Der Sanden BP, Huisman HJ, Heerschap A (1999) Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 10:295–304PubMedCrossRef

46.

Huisman HJ, Engelbrecht MR, Barentsz JO (2001) Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imag 13:607–614CrossRef

47.

Preziosi P, Orlacchio A, Giambattista G, Renzi P, Bortolotti L, Fabiano A, Cruciani E, Pasqualetti P (2003) Enhancement pattern of prostate cancer in dynamic MRI. Eur Radiol 13:925–930PubMed

48.

Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357–367PubMedCrossRef

49.

Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comp Assist Tomogr 15:621–628

50.

Brix G, Kiessling F, Lucht R, Darai S, Griebel J, Delorme S (2004) Microcirculation and microvasculature in breast tumors: quantitative characterization by pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 52:420–429PubMedCrossRef

51.

Port RE, Knopp MV, Hoffmann U, Milker-Zabel S, Brix G (1999) Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging 10:233–241PubMedCrossRef

52.

Mussurakis S, Buckley DL, Bowsley SJ, Carleton PJ, Fox JN, Turnbull LW, Horsman A (1995) Dynamic contrast-enhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma. Invest Radiol 30:650–662PubMedCrossRef

53.

Hulka CA, Edmister WB, Smith BL, Tan L, Sgroi DC, Campbell T, Kopans DB, Weisskoff RM (1997) Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837–842PubMed

54.

Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, Toyoshima S, Kuroki S, Ohno S (1996) Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200:639–649PubMed

55.

Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, Rabe J, van Kaick G (2004) Contrast-enhanced dynamic MR imaging for the assessment of microvessel density in prostate cancer. Eur Radiol 14:309–317PubMedCrossRef

56.

Liu PF, Krestin GP, Huch RA, Gohde SC, Caduff RF, Debatin JF (1998) MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging. Eur Radiol 8:1433–1440PubMedCrossRef

57.

Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schonberg SO, Vaupel P, van Kaick G (1998) Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4:2305–2312PubMed

58.

Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, Schonberg SO, Essig M, Vaupel P, van Kaick G (1998) Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 58:3598–3602PubMed

59.

Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97:172–187PubMedCrossRef

60.

Moehler TM, Hawighorst H, Neben K, Egerer G, Hillengass J, Max R, Benner A, Ho AD, van Kaick G, Goldschmidt H (2001) Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer 93:862–868PubMedCrossRef

61.

Nosas-Garcia S, Moehler T, Wasser K, Kiessling F, Bartl R, Zuna I, Hillengass J, Goldschmidt H, Kauczor HU, Delorme S (2005) Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging 22:154–162PubMedCrossRef

62.

Padhani AR (2003) MRI for assessing antivascular cancer treatments. Br J Radiol 76:60–80CrossRef

63.

Kiessling F, Farhan N, Lichy M, Vosseler S, Heilmann M, Krix M, Bohlen P, Miller DW, Mueller MA, Semmler W, Fusenig NE, Delorme S (2004) Dynamic contrast enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF-receptor 2 blockade with DC101. Neoplasia 6:213–223PubMedCrossRef

64.

Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, van Kaick G (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260–266PubMedCrossRef

65.

Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, Cohen RL, Brasch RC (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16:225–230PubMed

66.

Morgan B, Thomas A, Drevs J, Hennig J, Buchert, M, Jivan, A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O’Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964PubMedCrossRef

67.

Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward WP (2003) Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 30:32–38PubMed

68.

Preda A, Novikov V, Moglich M, Turetschek K, Shames DM, Brasch RC, Cavagna FM, Roberts TP (2004) MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 20:865–873PubMedCrossRef

69.

Brasch RC, Gossmann A, Helbich TH, Kuriyama N, Roberts TP, Shames DM, van Bruggen N, Wendland MF, Israel MA (2002) Can a small-molecular gadolinium contrast agent be applied successfully with dynamic MRI to quantitatively define brain tumor microvascular responses to angiogenesis inhibition? Acad Radiol 9 Suppl 2:326–327CrossRef

70.

Brasch R, Turetschek K (2000) MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 34:148–155PubMedCrossRef

71.

Roberts TP, Turetschek K, Preda A, Novikov V, Moeglich M, Shames DM, Brasch RC, Weinmann HJ (2002) Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol 9 Suppl 2:511–513CrossRef

72.

Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, Roberts TP (2004) Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 20:138–144PubMedCrossRef

73.

Bremer C, Mustafa M, Bogdanov A, Ntziachristos V, Petrovsky A, Weissleder R (2003) Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology 226:214–220PubMedCrossRef

74.

Dafni H, Israely T, Bhujwalla ZM, Benjamin LE, Neeman M (2002) Over-expression of vascular endothelial growth factor 165 drives peri-tumor interstitial convection and induces lymphatic drain: Magnetic resonance imaging, confocal microscopy, and histological tracking of triple labeled albumin. Cancer Res 62:6731–6739PubMed

75.

Ogawa S, Lee TM, Nayak AS, Glynn P (1990) Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magn Reson Med 14:68–78PubMedCrossRef

76.

Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M (1999) In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 59:5012–5016PubMed

77.

Gross DJ, Reibstein I, Weiss L, Slavin S, Stein I, Neeman M, Abramovitch R, Benjamin LE (1999) The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice. Clin Cancer Res 5:3669–3675PubMed

78.

Gross S, Gilead A, Scherz A, Neeman M, Salomon Y (2003) Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 9:1327–1331PubMedCrossRef

79.

Sawyer TK (2004) Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 13:1–19PubMedCrossRef

80.

Menger M, Glokler J, Rimmele M (2006) Application of aptamers in therapeutics and for small-molecule detection. Handb Exp Pharmacol 173:359–373PubMedCrossRef

81.

White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD, Sullenger BA (2003) Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci 9:295028–295033

82.

Mulder WJM, Strijkers GJ, van Tilborg GAF, Griffioe AW, Nicolay K (2006) Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 19:142–164PubMedCrossRef

83.

Colin M, Harbottle RP, Knight A, Kornprobst M, Cooper RG, Miller AD, Trugnan G, Capeau J, Coutelle C, Brahimi-Horn MC (1998) Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cells. Gene Ther 5(11):1488–1498PubMedCrossRef

84.

Nallamothu R, Wood GC, Pattillo CB, Scott RC, Kiani MF, Moore BM, Thoma LA (2006) A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation. AAPS PharmSciTech 7 (2) Article 32

85.

Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108:2270–2274PubMedCrossRef

86.

Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM (2003) Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel α_vβ₃-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res 63:5838–5843PubMed

87.

Mulder WJM, Strijkers GJ, Habets JW, Bleeker EJW, Schaft DWJ, Storm G, Koning GA, Griffioen AW, Nicolay K (2005) MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 19:2008–2010PubMed

88.

Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC (1998) Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4:623–626PubMedCrossRef

89.

Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F (2006) Specific targeting of tumor angiogenesis by RGD-conjugated APTMS-coated USPIO using a clinical 1.5 T MR-scanner. (in revision)

90.

Daldrup-Link HE, Simon GH, Brasch RC (2006) Imaging of tumor angiogenesis: current approaches and future prospects. Curr Pharm Des 12:2661–2672PubMedCrossRef

91.

Kang HW, Torres D, Wald L, Weissleder R, Bogdanov AA Jr (2006) Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer. Lab Invest 86:599–609PubMed

92.

Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, Kotyk JJ (2000) Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 44:433–439PubMedCrossRef

93.

Sipkins DA, Gijbels K, Tropper FD, Bednarski M, Li KC, Steinman LJ (2000) ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. Neuroimmunol 104:1–9CrossRef

94.

Crich SG, Bussolati B, Tei L, Grange C, Esposito G, Lanzardo S, Camussi G, Aime S (2006) Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res 66:9196–9201CrossRef

95.

Umathum R, Mangalathu Arumana, Semmler W, Bock M (2005) A solenoid receive array for multi-mouse imaging at 1.5 T. Proc. 13th Ann Meet Intl Soc Mag Reson Med:924

96.

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HBW, Lee TY, Mayr NA, Parker GJM, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232PubMedCrossRef

Titel: Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging
verfasst von: Fabian Kiessling
Manfred Jugold
Eva C. Woenne
Gunnar Brix
Publikationsdatum: 01.08.2007
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 8/2007
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-006-0566-x

Neu im Fachgebiet Radiologie

08.04.2024 | Andrologie | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging

Abstract

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2007

Percutaneous vertebroplasty in tumoral osteolysis

Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide

Intra-osseous meningioma of the orbit: an unusual presentation (2007: 5b)

Strategies for reduction of radiation dose in cardiac multislice CT

Digital mammography: what do we and what don’t we know?

Color Doppler, power Doppler and B-flow ultrasound in the assessment of ICA stenosis: Comparison with 64-MD-CT angiography

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie